Screening for hepatocellular carcinoma in patients with hepatitis C virus infection

Research Projects

Organizational Units

Journal Issue

Abstract

There is no evidence that it is beneficial to screen for hepatocellular carcinoma in symptomatic patients with HCV. (Strength of Recommendation [SOR]: C, based on a systematic review and case series studies.) Neither serum AFP measurement nor imaging is an ideal screening test. Patients can be screened for hepatocellular carcinoma using AFP measurement or ultrasonography; these tests have similar sensitivity and specificity. Computed tomography and magnetic resonance imaging offer increased screening sensitivity, but may be limited by cost and availability. (SOR: C, based on retrospective case series.) Combined testing with AFP measurement and ultrasonography improves sensitivity but decreases specificity.

Table of Contents

DOI

PubMed ID

Degree

Thesis Department

Rights

OpenAccess.

License

This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivs 3.0 License.